Inhaled Nitric Oxide Market Trends: A Forward-Looking Perspective
The global inhaled nitric oxide market is experiencing significant growth due to the rising prevalence of chronic illnesses and the potential applications of inhaled nitric oxide in treating these conditions. Chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD), Asthma, and Persistent Pulmonary Hypertension in Newborns (PPHN) have become major concerns for individuals and healthcare facilities worldwide, with mortality rates continuing to climb.
According to the World Health Organization (WHO), in 2019, asthma claimed approximately 461,000 lives globally, making it the most prevalent chronic illness, particularly among children. Furthermore, COPD, considered the third leading cause of death, resulted in 3.23 million fatalities worldwide in the same year. Alarmingly, cases related to PPHN are expected to rise, leading to higher mortality rates.
Inhaled nitric oxide has emerged as a valuable therapeutic option for these chronic illnesses, as it regulates and improves vascular muscle tone. It enhances oxygenation, reduces shunting, and improves ventilation-perfusion matching, making it a promising treatment for COPD, asthma, and PPHN. These factors are expected to drive the growth of the inhaled nitric oxide market in the coming years.
Inhaled Nitric Oxide’s Role in Combating COVID-19
The ongoing research on the use of inhaled nitric oxide in treating COVID-19 is garnering significant attention. Inhaled nitric oxide, as an endogenous vasodilator, is being explored for its potential to target pulmonary vasculature, particularly in conditions where higher pulmonary vascular resistance is needed. Current research indicates that inhaled nitric oxide improves oxygenation, a critical factor in fighting COVID-19.
Additionally, the pre-intubation application of inhaled nitric oxide in COVID-19 patients experiencing respiratory failure may have a substantial impact on enhancing patient outcomes. The various physiological effects provided by inhaled nitric oxide, including anti-inflammatory, antimicrobial, airway permeability, neurotransmission, and ciliary motility effects, could play a crucial role in treating a wide range of indications and symptoms of COVID-19. The potential of inhaled nitric oxide as a therapeutic agent in the fight against COVID-19 is expected to open up new opportunities, further driving the growth of the inhaled nitric oxide market.
Side Effects Raise Concerns
While inhaled nitric oxide offers numerous benefits in treating chronic ailments, there are concerns about potential side effects resulting from its overuse. Its role in oxygenation is linked to cellular cyclic GMP (cGMP), and an excessive increase in cGMP levels can interfere with normal cellular proliferation. Furthermore, inhaled nitric oxide can cause DNA strand alterations and mutagenic effects. In some cases, it can react with oxygen to produce potentially harmful irritants such as nitrogen dioxide. Overdosing or incorrect administration of inhaled nitric oxide may also lead to platelet aggregation blockage, potentially causing methemoglobinemia. Ongoing research into the toxic nature of inhaled nitric oxide may raise questions about its administration, potentially hindering the growth of the inhaled nitric oxide market.
North America Emerges as a Key Market
The inhaled nitric oxide market is witnessing significant growth opportunities in North America, driven by the increasing incidence of Acute Respiratory Distress Syndrome (ARDS) in developed countries. For example, the United States reports cases of ARDS at rates ranging from 64.2 to 78.9 per 100,000 person-years, highlighting the pressing need for therapies that enhance lung oxygenation and vascular health. Additionally, asthma affects approximately 25 million people in the region, with a higher prevalence among adult women. These factors are expected to propel the growth of the inhaled nitric oxide market in North America.
Key players in the inhaled nitric oxide market include Nu-Med Plus, Air Liquide, Merck, Praxair Technology Inc., Mallinckrodt, VERO Biotech, Halma Plc, Bellerophon Therapeutics Inc., and Linde Plc.
Global Industry Analysis (2018 – 2021) – Growth Trends and Market Forecast (2022 – 2029) https://www.fairfieldmarketresearch.com/report/inhaled-nitric-oxide-market
Visit Our Blogs:
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
This press release first seen on Brilad